Vanderbilt-Ingram Cancer Center Archive — Page 3 of 27
-
September 12, 2025
Study shows magnesium inhibits colorectal cancer carcinogenesis by increasing vitamin D-synthesizing bacteria
The findings from the current study suggest that magnesium also increases the gut synthesis of vitamin D, which does not go to the blood and takes effect locally. -
September 10, 2025
Vanderbilt-Ingram Cancer Center names associate directors and new program leaders
Shared resources at Vanderbilt-Ingram are designed to support and enhance cancer-relevant research and scientific interaction by providing access to cutting-edge technologies and services, as well as scientific expertise. -
September 2, 2025
Vanderbilt-Ingram Cancer Center announces Young Adult Cancer Symposium
The symposium offers clinicians, patients, caregivers and advocates the opportunity to learn from internationally known experts focused on early-onset cancers. -
August 28, 2025
Genetic analysis of people with African ancestry reveals lung cancer susceptibilities
Prior research has shown that Americans of African ancestry have a higher risk of lung cancer compared to white Americans despite smoking fewer cigarettes, but the reasons for this difference are not fully understood. -
August 19, 2025
Susan Morrow Legacy Foundation supports ovarian cancer research at Vanderbilt
The Susan Morrow Legacy Foundation has made a generous donation to support ovarian cancer research at Vanderbilt University and Vanderbilt University Medical Center. -
August 18, 2025
Photos and video from a memorable night: Stand Up to Cancer broadcast highlights Nashville talent, Vanderbilt-Ingram Cancer Center
Viewers saw performances by host Sheryl Crow, as well as the Jonas Brothers, Noah Cyrus, Gavin DeGraw, Marcus King, Brothers Osborne, Jon Pardi, Jelly Roll, Dan + Shay and CeCe Winans. -
August 1, 2025
Study reports final clinical trial data for advanced kidney cancer treatment
The drug combo pembrolizumab plus axitinib had sustained and durable clinical benefit in more than five years of follow-up. It is a standard-of-care first-line treatment for advanced kidney cancer.